All In Biotech

Drug Trial Radar · NCT06674577

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

A Multicenter, Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

750

Planned (sponsor's estimate)

Start

Dec 1, 2024

Primary completion

May 21, 2031

Study completion May 21, 2031

Sponsor

Lead sponsor
Vera Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to collect long-term safety and tolerability data for atacicept in patients with IgAN that completed Vera trial investigating atacicept in IgAN population.

Conditions

  • IgA Nephropathy (IgAN)
  • Renal and Urinary Disorders
  • Berger Disease

Interventions

  • Atacicept 150 mgDrug

    The atacicept drug product is available as a ready to use injection solution in the following prefilled syringe (PFS) that is composed of: \*BD Hypak™ SCF™ Barrel Glass barrel 1ml long with staked needle 27G ½" 5B with Rigid Needle Shield BD260 \*BD SCF™ Stopper 1ml long W4023 Flurotec

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events observed during the dosing periodTime frame: Baseline until end of study up to week156

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Vera Therapeutics

    Brisbane, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.